Astellas and the Institute of Medical Science at the University of Tokyo are expanding the range of diseases that can be covered by their rice-based oral vaccine, MucoRice.
The collaboration centers on Affinivax's multiple antigen presenting system to develop a vaccine targeted against pneumococcal disease.
The partnership will develop a rice-based oral vaccine against cholera and E. coli-related diarrheal diseases.
Astellas' recently approved anti-fungal drug could be used to treat immunocompromised patients facing life threatening fungal infections.
The Osaka-Astellas joint research chair will focus on developing cell therapy technologies.
The partnership between Astellas and Cancer Research Technology will begin with the development of drugs for pancreatic cancer targeting autophagy.
Two of Japan's largest pharmaceutical firms will share their drug libraries, making 400,000 compounds available for high throughput sequencing.